Delivery Order SPE2DB22D3016-SPE2DB25FBCK1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $8,504.62 on September 19, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 10, 2025, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside award made through open competition, reflecting AmerisourceBergen's demonstrated capability to fulfill...
- The Defense Logistics Agency awarded a delivery order valued at $17,009.24 to AmerisourceBergen Drug Corp for the supply of Tecentriq 840 mg/14 ml vials. This firm fixed-price, competitively awarded contract was issued on August 12, 2025, with an ultimate completion date of September 3, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside acquisition, this delivery order was open to competition among qualified...
- The Defense Logistics Agency awarded a $17,009.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Tecentriq (atezolizumab) 840 mg/14 mL vials on May 19, 2025, with completion targeted for June 10, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, which carries a $999,999,999 ceiling and runs through December 2026. The pharmaceutical distributor is...
- The Defense Logistics Agency awarded a $25,189 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tecentriq Hybridza 1,875 mg 15 ml pharmaceutical product. This is a non-set-aside competitive award with an ultimate completion date of September 30, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Tecentriq 840 mg/14 ml vials. The contract is valued at $17,009.24 under a firm fixed-price arrangement with an ultimate completion date of May 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of TECENTRIQ 840 MG/14 ML VIAL 14ML. The $8,016.30 firm fixed price contract has a completion date of June 4, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to deliver a wide range of pharmaceutical products and medical supplies...
- The Defense Logistics Agency awarded a $7,857.72 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 4561918282 TECENTRIQ 840 MG/14 ML VIAL 14ML pharmaceutical products. Amerisourcebergen Drug Corporation will deliver the products to a location in Conshohocken, Pennsylvania by September 14, 2023 under the terms of the order. The prime contractor, Amerisourcebergen Drug Corporation, is a division of Amerisourcebergen Corporation. No subcontractors or set...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide TECENTRIQ 840 MG/14 ML VIAL 14ML. This $8,016.30 contract has a completion date of March 28, 2024. Amerisourcebergen Drug Corp is the prime contractor and does not have any major subcontractors mentioned. The contract was awarded through DLA Troop Support Medical, which is responsible for supplying pharmaceuticals, medical...
- The Defense Logistics Agency Troop Support Medical awarded a $23,573 firm fixed price delivery order to Amerisourcebergen Drug Corp Corporate Office Division. The order is for the delivery of 4561624088 TECENTRIQ 840 MG/14 ML VIAL 14ML pharmaceutical products to a location in Conshohocken, Pennsylvania. The period of performance for this delivery is from July 27, 2023 to August 17, 2023. No major subcontractors or set aside designations were indicated. This order was issued under an existing DLA...
- Amerisourcebergen Drug Corp has received a $7,857.74 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical to supply TECENTRIQ 840 MG/14 ML VIAL 14ML pharmaceutical products. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania by December 29, 2023. No set-aside designation was applied to this award made against an indefinite-delivery contract held by Amerisourcebergen with DLA Troop Support Medical to provide...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBCK1Delivery Order
The Defense Logistics Agency awarded a $17,009.24 delivery order to AmerisourceBergen Drug Corp for Tecentriq 840 mg/14 ml vials on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and a major distribution hub for federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. Tecentriq, a specialized oncology medication, exemplifies the type of critical therapeutic agent AmerisourceBergen delivers through its federal contract portfolio, demonstrating the company's role as a vital supplier of brand-name and generic pharmaceuticals supporting military and federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.0k | 7/21/25 |